Cell line engineering, also referred to as cell line editing, involves the genetic modification of cell lines to determine the effects of specific genetic alterations. By studying phenotypic changes in these cells, scientists can advance the discovery of new drugs and therapies for various types of cancers.
on this page
Biocytogen, with over a decade of engineering experience, has successfully modified a variety of cell lines. The company integrates gene editing technologies such as EGE, ES, and has developed humanized cell lines targeting immune checkpoints (e.g., PD-L1), tumor-specific antigens (e.g., HER2, TROP2), and other immune cell-associated cell lines. These cell lines are relevant to colon cancer, melanoma, hepatocellular carcinoma, breast cancer, and other solid tumors. These achievements have significantly improved the efficiency of research and development in tumor immunotherapy, monoclonal antibody, bispecific antibody, polyclonal antibody, tumor vaccine, and ADC drug optimization, establishing Biocytogen as a key tool for preclinical research.
• 310728
• 310701
• 311584
C57BL/6 • 311537
